The new era in personalized cancer treatment has brought a welcome surge in the number of new US Food and Drug Administration–approved oral antineoplastic agents. However, this paradigmatic change requires prescribers to be much more knowledgeable about drug absorption, metabolism, and transport as the potential for drug-drug interactions is high. Most oral antineoplastic drugs approved since 2010 are associated with multiple, clinically significant drug-drug interactions (DDIs) (Table). The risk for these DDIs is increased by concurrent medications prescribed for preexisting chronic diseases common in the aging oncology population, and by the complexity associated with obtaining these expensive oral chemotherapy agents through specific pharmacy restriction programs.
Parsad S, Ratain MJ. Drug-Drug Interactions With Oral Antineoplastic Agents. JAMA Oncol. Published online October 13, 2016. doi:10.1001/jamaoncol.2016.3323